title: Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis.
abstract: Multiple sclerosis (MS) is a neurological disorder that affects more than a million people world-wide. The aetiology of MS is not known and there is no medical treatment available that can cure MS. Experimental autoimmune encephalomyelitis (EAE) is a T-cell-mediated autoimmune disease model of MS. The pathogenesis of EAE/MS is a complex process involving activation of immune cells, secretion of inflammatory cytokines and destruction of myelin sheath in the central nervous system (CNS). Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptor transcription factors that regulate cell growth, differentiation and homeostasis. PPAR agonists have been used in the treatment of obesity, diabetes, cancer and inflammation. We and others have shown that PPARgamma, alpha and delta agonists inhibit CNS inflammation and demyelination in the EAE model of MS. In this study we show that the PPARdelta agonists GW501516 and L165041 ameliorate MOGp35-55-induced EAE in C57BL/6 mice by blocking interferon (IFN)-gamma and interleukin (IL)-17 production by T helper type 1 (Th1) and Th17 cells. The inhibition of EAE by PPARdelta agonists was also associated with a decrease in IL-12 and IL-23 and an increase in IL-4 and IL-10 expression in the CNS and lymphoid organs. These findings indicate that PPARdelta agonists modulate Th1 and Th17 responses in EAE and suggest their use in the treatment of MS and other autoimmune diseases.
authors.affiliation: Neuroscience Research Laboratory, Methodist Research Institute, Indianapolis, IN 46202, USA.
authors.forename: Saravanan
authors.initials: S
authors.lastname: Kanakasabai
authors.forename: Wanida
authors.initials: W
authors.lastname: Chearwae
authors.forename: Crystal C
authors.initials: CC
authors.lastname: Walline
authors.forename: Wade
authors.initials: W
authors.lastname: Iams
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Adams
authors.forename: John J
authors.initials: JJ
authors.lastname: Bright
mesh_terms: D000818:Animals; D016764:Cell Polarity; D002478:Cells, Cultured; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D005260:Female; D020381:Interleukin-17 / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D047494:PPAR delta / Q000819:agonists* / Q000172:deficiency / Q000276:immunology; D010642:Phenoxyacetates / Q000494:pharmacology*; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D018417:Th1 Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: C520164:4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid; C425931:GW 501516; D020381:Interleukin-17; D047494:PPAR delta; D010642:Phenoxyacetates; D013844:Thiazoles
references.citation: Immunity. 2003 Nov;19(5):641-4
references.pmid: 14614851
references.citation: J Immunol. 2004 May 1;172(9):5790-8
references.pmid: 15100326
references.citation: Science. 1999 Feb 26;283(5406):1277-8
references.pmid: 10084932
references.citation: Eur J Immunol. 2000 Feb;30(2):498-508
references.pmid: 10671205
references.citation: J Immunol. 2002 Jun 15;168(12):6506-13
references.pmid: 12055272
references.citation: J Immunol. 2002 Mar 1;168(5):2508-15
references.pmid: 11859145
references.citation: J Autoimmun. 2008 Nov;31(3):252-6
references.pmid: 18502610
references.citation: Scand J Immunol. 2006 May;63(5):330-7
references.pmid: 16640656
references.citation: J Neuroimmunol. 2006 Sep;178(1-2):76-86
references.pmid: 16844232
references.citation: J Exp Med. 2009 Sep 28;206(10):2079-89
references.pmid: 19737866
references.citation: J Clin Invest. 2003 Oct;112(8):1186-91
references.pmid: 14561703
references.citation: J Immunol. 2000 Feb 1;164(3):1364-71
references.pmid: 10640751
references.citation: Mol Cell Biol. 2000 Jul;20(14):5119-28
references.pmid: 10866668
references.citation: J Clin Immunol. 2004 Sep;24(5):542-52
references.pmid: 15359113
references.citation: Cell. 1992 Mar 6;68(5):879-87
references.pmid: 1312391
references.citation: J Neuroimmunol. 2005 Nov;168(1-2):65-75
references.pmid: 16098614
references.citation: Eur J Immunol. 1998 Dec;28(12):3893-903
references.pmid: 9862326
references.citation: Atherosclerosis. 2005 Jul;181(1):29-37
references.pmid: 15939051
references.citation: Genes Immun. 2002 Apr;3(2):59-70
references.pmid: 11960303
references.citation: J Exp Med. 1995 Jan 1;181(1):381-6
references.pmid: 7528773
references.citation: Nat Med. 2008 Mar;14(3):337-42
references.pmid: 18278054
references.citation: Immunol Today. 1995 Aug;16(8):383-6
references.pmid: 7546194
references.citation: Nature. 1992 Aug 27;358(6389):771-4
references.pmid: 1324435
references.citation: J Exp Med. 1995 Feb 1;181(2):817-21
references.pmid: 7836934
references.citation: J Neuroimmunol. 2001 May 1;116(1):40-8
references.pmid: 11311328
references.citation: Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4277-82
references.pmid: 18337495
references.citation: Nature. 2003 Feb 13;421(6924):744-8
references.pmid: 12610626
references.citation: J Immunol. 2003 Dec 1;171(11):5743-50
references.pmid: 14634082
references.citation: Am J Pathol. 1997 Jun;150(6):1909-17
references.pmid: 9176384
references.citation: J Immunol. 2007 Feb 15;178(4):2589-98
references.pmid: 17277169
references.citation: Nature. 1998 Jan 1;391(6662):82-6
references.pmid: 9422509
references.citation: Eur J Immunol. 2009 Jul;39(7):1864-9
references.pmid: 19544494
references.citation: Glia. 2001 Mar 1;33(3):191-204
references.pmid: 11241737
references.citation: Clin Sci (Lond). 2008 Aug;115(4):107-27
references.pmid: 18616431
references.citation: Ann Neurol. 2002 Jun;51(6):694-702
references.pmid: 12112074
references.citation: J Neurosci Res. 2006 May 15;83(7):1299-309
references.pmid: 16547967
references.citation: Neurosci Lett. 2004 Jul 8;364(3):173-8
references.pmid: 15196670
references.citation: N Engl J Med. 2000 Sep 28;343(13):938-52
references.pmid: 11006371
references.citation: J Virol. 1999 Feb;73(2):1637-9
references.pmid: 9882371
references.citation: Brain Res. 2003 Jun 13;975(1-2):10-21
references.pmid: 12763589
references.citation: J Immunol. 2008 Oct 15;181(8):5681-90
references.pmid: 18832727
references.citation: J Neuroimmunol. 2005 Oct;167(1-2):99-107
references.pmid: 16091293
references.citation: J Neuroimmunol. 1996 Oct;70(1):87-90
references.pmid: 8862139
references.citation: J Neuroimmunol. 1998 Feb;82(1):22-30
references.pmid: 9526842
references.citation: J Neurosci Res. 1998 Mar 1;51(5):563-73
references.pmid: 9512000
references.citation: Autoimmunity. 1999;31(4):237-48
references.pmid: 10789989